At a glance
ClinicalIndex Comparison RecordN/ACompleted· 1,235 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Observational, Prospective, Multinational, Multicentre Study Comparing the Effectiveness of Safinamide, Rasagiline and Other "Standard Of Care" as Add-On Therapy to Levodopa (L-Dopa) in Parkinson's Disease (Pd) Fluctuating Patients
In Brief
An observational study for Parkinson's Disease. Completed, enrolled 1,235 participants across 3 sites in 3 countries.
Detailed Summary
The purpose of this study is to evaluate how safinamide, rasagiline and other SoC drugs are associated with the quality of life of PD patients by means of the Parkinson's Disease Questionnaire (PDQ)-39 items.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson's Disease
CountriesGermany, Italy, Spain
CollaboratorsIQVIA Pty Ltd
Timeline
N/ACompletedFinished
2020202120222023202420252026
First PostedJun 2019
Enrollment StartDec 2019
Primary CompletionDec 2023
TodayJul 2026
First PostedJun 21, 2019
Enrollment StartDec 3, 2019
Primary CompletionDec 31, 2023
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 7.0 years ago